Merck & Co., Inc. vs Noble Corporation plc — how do they compare? Merck & Co., Inc. trades at $146.19 (market cap $351.28B), while Noble Corporation plc trades at $42.5 (market cap $6.73B). The key difference: Merck & Co., Inc. is far larger — about 52.2× Noble Corporation plc's market cap, and Noble Corporation plc pays the higher dividend (4.74%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Noble Corporation plc for 26 Days on average.
| MRK | NE | |
|---|---|---|
Market Cap | $351.28B | $6.73B |
Volume | 7,969,665 | 1,027,635 |
Sector | Health | Energy |
52-Week High | $156.43 | $54.37 |
52-Week Low | $82.49 | $26.70 |
Typical Hold Time | 98 Days | 26 Days |
Enterprise Value | $398.04B | $8.16B |
Dividend Yield | 2.39% | 4.74% |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Noble Corporation (NE) trades at $42.56, up 3.88% today, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported $3.29B revenue for 2025 with a 4.88% net income margin, though recent quarterly earnings have been inconsistent with two misses and one beat. Analyst sentiment is divided with a $52 consensus price target representing 22% upside potential, but ongoing legal investigations create uncertainty.
The stock presents a moderate opportunity with significant analyst upside potential, supported by recent contract wins including the long-term Ghana drilling agreement. However, risks include inconsistent earnings performance, declining profitability margins from 2025 to 2026, and multiple ongoing legal investigations that could impact investor confidence and stock performance in the near term.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →